

## ACKNOWLEDGEMENTS

*Foremost, I would like to express my sincere gratitude to my guide Prof. Shubhini A. Saraf, Head and Dean of the Department School of Bioscience and Biotechnology, Babasaheb Bhimrao Ambedkar University, for the continuous support of my Ph.D. research. This work would not have been possible without her guidance and involvement, her support and encouragement on daily basis from the start of the project till date. Under her guidance I successfully overcame many difficulties and learnt a lot. Her own zeal for perfection, unflinching courage and conviction has always inspired me to do more. She has taught me another aspect of life, that, “Goodness can never be defied and good human beings can never be denied”. For all this, I sincerely thank her from bottom of my heart and will be truly indebted to her throughout my life time. I could not have imagined having a better advisor and mentor for my Ph.D.*

*I wish to offer my sincere thanks to Prof. R.C. Sobti, Honourable Vice Chancellor of Babasaheb sahib Bhimrao Ambedkar University, Lucknow for providing infrastructure facilities for carrying the project advices throughout my academic career.*

*Besides my advisor, I would like to thank the rest of committee members: Dr. R. Venkatsh Kumar, Dr. N.K.S. More, Dr. V Elangovan, Dr. Gaurav Kaithwas, Dr. Sudipta Saha, for their encouragement, insightful comments, and meaningful queries.*

*My sincere thanks also go out to Prof. Shailendra K. Saraf, Director (pharm.) BBDNITM, Lucknow, for providing me approval and facilities for animal studies from Institutional Animal Ethical Committee.*

*I am also thankful to Dr. Krishna P. Gupta, former Sr. Principal Scientist at CSIR-Indian Institute of Toxicology Research (Formerly ITRC) for providing me lab facilities as well as approval and guidance for another part of animal studies.*

*I would also like to express my gratitude to Mr. Subrata for Scientific Assistance at Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Mumbai.*

*I am thankful to all my classmates in BBAU, Dept. of Pharmaceutical Sciences, Mahendra singh, Jovita Kanoujia.*

*I am also grateful to my juniors Malti Arya, Chandra Bhusahn Tripathi, Poonam Parashar Swetlana Gautam, Manjiri Singh, Jitendar Kumar Rawat, Subhadeep Roy, Rajnish Yadav,*

*Amit Rai, Vineet Raj, Amit Keshari, and Ashok Singh, for the stimulating discussions, working together before deadlines, and for all the fun we have had in the last four years.*

*I am also thankful to my friend in ICT, Mumbai, Dr. Preeti for helping me to resolve problems in my research.*

*I wish to thank the staff members of Mr. Ramesh, Mr.Anand, Mrs.Pooja, Ms.Gunjan, Mr. Amar and Mr.Bhandari.*

*Finally, I acknowledge the people who mean a lot to me, my parents and in laws for showing faith in me and giving me liberty to choose what I desired. Also I express my thanks to my brother Abhishek and sister Veenita for their support and valuable prayers. I owe thanks to a very special person, my husband, Abhishek Singh for his help to get samples for research and understanding during my pursuit of Ph.D degree that made the completion of research possible. You were always around at times I thought that it is impossible to continue, you helped me to keep things in perspective. I appreciate my little one, Atharv for abiding my ignorance and the patience he showed during my degree. Last but not the least, I wish to thank almighty God who keep his blessings on me every second and giving me the strength and patience to work through all these years so that today I can stand proudly with completion of my research work.*

## TABLE OF CONTENTS

Sr. No.	Title	Page no.
1.	Acknowledgments	i-ii
2.	List of Tables	iv-vi
3.	List of Figures	vii-x
4.	List of symbols and abbreviations	xi

Sr. No.	Title	Page no.
1.	Introduction	1-48
2.	Analytical Profiles	49-73
3.	Preformulation Studies	74-92
4.	Methodology: Development, Characterization and Optimization	93-151
5.	Ex vivo and In vivo evaluation	152-186
6.	Summary and Conclusion	187-195
	Publications	
	Appendix I	
	Appendix II	
	Appendix III	

## LIST OF TABLES

Table No.	Table Caption	Page no.
1	Comparison of different production techniques with advantage and limitations	17
2	List of Phytoconstituents with their mechanism of action	25
3	Silymarin monograph listed in different Pharmacopoeia	55
4	Marketed formulation of Fluorouracil	61
5	Solubility of silymarin in various liquid lipids and surfactants	77
6	Amount of solid lipid required to solubilize 10 mg of silymarin	77
7	UV absorbance of silymarin in methanol	79
8	Parameters of Silymarin calibration curve	80
9	Contemplation of standard curve of silymarin in methanol	80
10	UV absorbance of silymarin in 5% v/v methanolic phosphate buffer pH 6.8	81
11	Contemplation of standard curve of silymarin in 5% v/v methanolic phosphate buffer of pH 6.8	82
12	UV absorbance of 5-Fluorouracil in methanol	84
13	UV absorbance of 5-Fluorouracil in 5% v/v methanolic phosphate buffer pH 6.8	85
14	Comparison of different methods of preparation of NLC	95
15	Variables and their control values in $2^3$ (i.e. three factors at two levels) full factorial design	97
16	Behaviour of various concentrations of gelling agents for NLC	100
17	Composition of silymarin-NLC gel	100

18	Responses results of various regression analysis	105
19	Response values (Z-Ave, PI and ZP) for three factors of the eight experiment formulations	105
20	Optimization of variables	106
21	Obtained Predicted and experimental values based on optimization of process parameters by Design of Expert software	106
22	Value of Entrapment Efficiency (%) of various formulations	113
23	Stability evaluation of Silymarin NLC 3 gel as per ICH guidelines	115
24	Variables and their control values in $2^3$ (i.e. Three factors at two levels) full factorial design	116
25	Composition of the lipid and silymarin in Silymarin NLC	118
26	Composition of silymarin-NLC gel	121
27	Behaviour of various concentrations of gelling agents for NLC	121
28	Mean Particle size (Z-Ave) and entrapment efficiency (EE %) for the eight experimental formulations	126
29	Optimization of variables	127
30	Responses results of various regression analysis	127
31	Obtained Predicted and experimented values based on optimization of process parameters by Design of Expert software	128
32	Regression coefficients for drug release from, NLC 9 for different model	138
33	Stability evaluation of Silymarin NLC 9 gel as per ICH guidelines	140
34	Composition of the lipid and drug in NLC	141
35	Composition of Silymarin/5-Fluorouracil NLC gel	143
36	Physicochemical characterization of Silymarin-5-Fluorouracil NLC	146
37	Scoring system for skin reaction	154
38	Grading of rat dorsal skin wrinkles according to the scale	156
39	Treatment details of optimised Silymarin NLC 9 gel	157

40	Nucleotide sequences used for RNA analysis by RT-PCR for NLC 9	159
41	Observation of erythema and edema after application of silymarin-NLC9 gel	170

## LIST OF FIGURES

Figure No.	Figure Caption	Page No.
1	Different Methods to improve drug penetration through the skin	5
2	Drug incorporation models of SLNs (a) solid solution model, (b) core-shell model (drug-enriched Shell) and (c) core-shell model (drug-enriched core)	9
3	Structures of NLC. Class I (Imperfect type), Class II (Non crystalline, amorphous), Class III (Multiple type)	11
4	Diagram presentation of hot high pressure homogenization and cold high pressure homogenization	13
5	Homogenization technique in the production of lipid carrier system	14
6	Emulsification solvent evaporation technique in the preparation of lipid carrier system	15
7	High shear homogenization and ultrasonication techniques in the preparation of NLC	16
8	Milk thistle plant with flower	49
9	Chemical and three dimensional structure of silymarin	51
10	Chemical structures of the silymarin flavonolignans from milk thistle	51
11	Certificate of Analysis	57
12	Chemical structure of Fluorouracil	58
13	Chemical structure of Glycerol monostearate	62
14	Chemical structure of Oleic acid	63
15	Chemical structure of Glyceryl behenate	65
16	IR spectra of pure silymarin	75

17	Calibration curve of silymarin in methanol	79
18	Standard curve of silymarin in 5% v/v methanolic phosphate buffer pH 6.8	82
19	Calibration curve of 5-Fluorouracil in methanol	84
20	Standard curve of 5-Fluorouracil in 5% v/v methanolic phosphate buffer pH 6.8	86
21	FT-IR of Silymarin (I), and physical mixture of Silymarin with Glycerol monostearate (II)	87
22	Pareto chart of the analyzed effects for the Z-Ave (a) and for the ZP (b)	107
23	Surface response chart: effect of the Pressure (bars) and Speed (rpm) on the ZP	109
24	Zeta potential observation of NLC formulations	111
25	Transmission electron microscopy of Silymarin NLC 3 gel	114
26	Surface response chart from top to bottom: the effect of the surfactant concentration (%) and lipid amount on particle size, and on entrapment efficiency	130
27	Cubical representation of effect of lipid amount, surfactant concentration and pressure on particle size (top) and entrapment efficiency (bottom)	132
28	Pareto chart of the analyzed effects for the Z-Ave and for the ZP (from top to bottom)	133
29	DSC thermograms of Silymarin (A), Compritol ATO 888(B), and the lyophilized NLC 9 sample(C)	135
30	Transmission electron microscopy of Silymarin NLC 9 gel	136
31	Comparative <i>in vitro</i> release of silymarin from NLC 9gel and SILYMARIN® P (marketed formulation) at the end of 24 h	138
32	Photo degradation profile of Silymarin-NLC and methanolic solution of Silymarin at various time points	139
33	Transmission electron microscopy of Silymarin-5-Fluorouracil NLC gel	144
34	Protective effect of Silymarin in NLC 9 gel on DMBA induced deregulation of ODC, PCNA, COX-2 and Cyclin D1. Qualitative and	158

	quantitative analysis of ODC, PCNA and COX-2 and Cyclin D1 at protein level (n=3) is shown in (I) and at mRNA level in (II), I-Placebo formulation, II-DMBA+ Placebo formulation, III-DMBA+IP6 in acetone, IV-DMBA+NLC gel, V-DMBA+ Silymarin	
35	Effect of topically applied Silymarin-NLC 9 gel on UV-induced skin Edema in rat skin: UV induced skin without any treatment and after treatment of Silymarin NLC gel (from top to bottom)	160
36	Comparative silymarin permeation profile of NLC 9 gel and SILYMARIN® P (marketed formulation)	161
37	Anticancer activity of silymarin on SK-MEL-2. Graph showing the percentage proliferative inhibition values of NLC 9 gel, Phytosome (marketed) and control on cell line. All values are average of triplicates	162
38	Effect of Silymarin-NLC 9 gel on migration and invasion without any treatment and after Silymarin-NLC treatment (from left to right) on SK-MEL-2 cells after 48-hr treatment	163
39	Cell line SK-MEL-2 after Silymarin NLC 9 gel application and before silymarin application (from top to bottom)	165
40	Cell line SK-MEL-2 before silymarin-5-fluorouracil gel application and after silymarin-5-fluorouracil gel application (from top to bottom)	167
41	Percentage inhibition of UV-induced Edema in rats after topical application of Silymarin NLC 9 gel in comparison to Phytosome (marketed)	171
42	Inhibitory effect of Silymarin NLC 9 gel on DMBA-induced activity in albino mice, COX-2,Cyclin D1,ODC and PCNA activity at protein level was measured by western blot analysis. Each data bar represents the mean $\pm$ SD of four mice; each sample was assayed in triplicate. I-Placebo formulation, II- DMBA+ Placebo formulation, III- DMBA+IP6 in acetone, IV-DMBA +NLC ,V-DMBA +Silymarin. Bars represent the standard deviation. * 'p' < 0.05, ** 'p' < 0.01,,***'p'< 0.001with respect to positive control. # 'p' <0.05, ## 'p'< 0.01, ### 'p' < 0.001 with respect to DMBA, when the comparison was done between the effects of individual with that of combination treatment at different time points.	175, 176
43	Inhibitory effect of Silymarin NLC 9 gel on DMBA-induced activity in albino mice, COX-2,Cyclin D1,ODC and PCNA activity at m-RNA was measured by PCR analysis. Each data bar represents the mean $\pm$ SD of four mice; each sample was assayed in triplicate. I- Placebo formulation, II-DMBA+ Placebo formulation, III- DMBA+IP6 in acetone, IV-DMBA+NLC. V-DMBA +Silymarin. Bars represent the standard deviation. * 'p' < 0.05, ** 'p' < 0.01,***'p'< 0.001,with respect to positive	177- 179

	control. # 'p' <0.05, ## 'p' < 0.01,# 'p' <0.001 with respect to DMBA, when the comparison was done between the effects of individual with that of combination treatment at different time points	
--	---	--

## LIST OF SYMBOLS AND ABBREVIATIONS

1.	SLN	Solid lipid nanoparticles
2.	NLC	Nano structured lipoidal carrier
3.	HHPH	Hot High Pressure Homogenization
4.	UV	Ultra violet
5.	IR	Infra-red
6.	FT-IR	Fourier transform infrared spectroscopy
7.	TDS	Topical delivery system
8.	DSC	Differential scanning calorimetry
9.	SRB	Sulfo rhodamine-B assay
10.	RT-PCT	Reverse transcription polymerase chain reaction
11.	IAEC	Institutional animal ethics committee
12.	ICH	International conference on harmonisation
13.	IC <sub>50</sub>	Inhibition concentration 50
14.	LD <sub>50</sub>	Lethal dose 50 %
15.	PI	Polydispersity index
16.	ZP	Zeta potential
17.	CMC	Critical Micelle concentration
18.	GRAC	Generally regarded as safe
19.	DLS	Dynamic light scattering
20.	EE	Entrapment efficiency
21.	DL	Drug Loading
22.	HPMC	Hydroxy propyl methylcellulose
23.	TEM	Transmission electron micrographic
24.	ANOVA	Analysis of variance
25.	5-FU	5-Fluorouracil
26.	PBS	Phosphate buffer solution
27.	TCA	Trichloroacetic acid
28.	RNA	Ribonucleic acid
29.	DNA	Deoxy nucleic acid
30.	CPCSEA	Committee for the Purpose of Control and Supervision of Experiments on Animals
31.	SDS-PAGE	Sodium dodecyl sulfate polyacrylamide electrophoresis
32.	EGTA	Ethylene glycol tetra acetic acid
33.	PVDF	Polyvinylidenedifluoride
34.	ODC	Ornithine decarboxylase
35.	PCNA	Proliferating cell nuclear antigen
36.	HRP	Horseradish peroxidase
37.	mRNA	Messenger Ribonucleic acid
38.	DMBA	Dimethylbenz[a]anthracene
39.	Ip 6	Inositol phosphate
40.	Z-Ave	Mean particle size